Cost effectiveness of trastuzumab in adjuvant treatment of early breast cancer: A model based analysis

被引：0
|
作者：
Dedes, Konstantin J.
Szucs, Thomas D.
Imesch, Patrick
Fehr, Mathias K.
Fink, Daniel
机构：
[1] Univ Zurich Hosp, Div Gynecol, CH-8091 Zurich, Switzerland
[2] Univ Zurich, Inst Social & Prevent Med, CH-8006 Zurich, Switzerland
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE
    Macedo, A.
    Monteiro, I
    Ray, J. A.
    Cirrincione, A.
    Andrade, S.
    Pereira, C.
    VALUE IN HEALTH, 2008, 11 (06) : A472 - A472
  • [42] Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    PHARMACOECONOMICS, 2018, 36 (03) : 381 - 382
  • [43] Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    PharmacoEconomics, 2018, 36 : 381 - 382
  • [44] Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    PharmacoEconomics, 2018, 36 : 505 - 505
  • [45] COST-EFFECTIVENESS OF ANASTROZOLE AS ADJUVANT TREATMENT FOR EARLY STAGES BREAST CANCER IN POSTMENOPAUSAL WOMEN
    Rudakova, A., V
    VALUE IN HEALTH, 2009, 12 (07) : A276 - A276
  • [46] COST-EFFECTIVENESS OF ANASTROZOLE, IN COMPARISON WITH TAMOXIFEN, IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER IN BRAZIL
    Fonseca, Marcelo
    Araujo, Gabriela T. B.
    Saad, Everardo D.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2009, 55 (04): : 410 - 415
  • [47] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE FOR THE ADJUVANT TREAT OF PATIENTS WITH RESIDUAL INVASIVE HER2+EARLY BREAST CANCER IN GREECE
    Naoum, V
    Antonaki, M.
    Kakouros, M.
    Hansen, S. A.
    Ouzounelli, M.
    Tziarou, N.
    VALUE IN HEALTH, 2022, 25 (12) : S173 - S173
  • [48] Cost-effectiveness of adjuvant chemotherapy in early stage breast cancer
    John, Preethi
    Bannuru, Raveendhara R.
    Cohen, Joshua T.
    Buchsbaum, Rachel J.
    Erban, John Kalil
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [49] Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
    Ishihara, Mikiya
    Mukai, Hirofumi
    Nagai, Shunji
    Mukohara, Toru
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) : 431 - 435
  • [50] Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer
    Mikiya Ishihara
    Hirofumi Mukai
    Shunji Nagai
    Toru Mukohara
    International Journal of Clinical Oncology, 2009, 14 : 431 - 435
12345